Sativex Mouth Spray
LONDON, June 18 (Reuters) - GW Pharmaceuticals Plc’s (GWP.L) cannabis-derived medicine Sativex has been approved in Britain for treating spasticity in patients with multiple sclerosis, in a landmark decision for the small drugmaker. AThe much-delayed product was finally granted a British licence on Thursday, an official from the Medicines and Healthcare products Regulatory Agency (MHRA) told Reuters on Friday. AThe company later issued a statement confirming the move. AClinical trials have shown GW’s Sativex, which is sprayed under the tongue, reduces spasticity in multiple sclerosis (MS) in patients who do not respond adequately to existing therapies. AIt became the world’s first cannabis medicine to win regulatory clearance when it was approved in Canada in 2005 for neuropathic pain but its roll-out in Britain — and other European markets thereafter — is a larger sales opportunity.
Posted: June 19th, 2010
at 11:50pm by Koookiecrumbles
Categories: too good to be true,drogas,business,mnp is for the children,real life news,science,development,health
Comments: No comments